PREFACE This is my 17th year attending American Society of Hematology (ASH) Annual Meeting, where typically over 30,000 attendees from all over the world (hematologists/oncologists, lab researchers,...
JACK AIELLO
Diagnosed with myeloma in 1995, Jack is strong proponent of patients participating in clinical trials so that, in the future, myeloma and other cancers will be known as curable diseases. He is a proud facilitator of the San Francisco Bay Area Myeloma Support Group
Follow Jack on Twitter: @JackMAiello
Support Group Website: Multiple Myeloma Support for the SF Bay Area (sfbayareamyelomasupport.org)
MYELOMA HIGHLIGHTS FROM ASH CONFERENCE “VIRTUALLY” 12/9-12/2022
Day 3 ASH: It’s a Wrap!
Today was the final day of ASH, but it was still full of information, and to be honest, I’m a bit brain-fried. For me, the day started with an excellent Education Spotlight session on...
Day 2 ASH: Some new drugs, new processes
Today’s oral presentations examined prognostic factors for newly diagnosed multiple myeloma patients, new drugs, and optimized treatment approaches, as well as prognostic markers. I’ll show some of...
Day 1 ASH: From IMWG to Bispecifics and more…
Today, I began at 4 a.m. PST for the privilege of being able to attend the International Myeloma Working Group (IMWG) meeting. The IMWG has more than 260 myeloma specialists who meet twice a year....
Pre-ASH Blog: Hybrid meeting (virtual for me), Exciting updates
There is no other single conference where so much information is presented about myeloma. Information about so many topics is provided: how to treat MM patients in various stages; results of phase...